IGC PharmaIGC +0.36%29 Receivables Turnover is 12.94 as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 838 Biotechnology companies, IGC Pharma ranks better than 93.56% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. IGC Pharma's Revenue for the
three
months ended in Mar. 2026 was $0.32 Mil. IGC Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.02 Mil.
Hence, IGC Pharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 12.94.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
IGC Pharma Receivables Turnover Related Terms
IGC Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for IGC Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC vs SER, NRSN, PVCT: Receivables Turnover Comparison
For the Biotechnology subindustry, IGC Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC) has a Receivables Turnover of 12.94 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #54 out of 838 companies in the Biotechnology industry, placing it in the top 6.4%.
Is IGC Pharma's Receivables Turnover too high?
IGC Pharma's current Receivables Turnover is 12.94. The Biotechnology industry median Receivables Turnover is 5.28. IGC Pharma's value of 12.94 is 145.3% above this industry median. Based on the distribution chart, IGC Pharma ranks #54 out of 838 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Receivables Turnover compare to SER and NRSN?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #54 out of 838 companies for Receivables Turnover. This places IGC Pharma in the top 6% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. IGC Pharma's value of 12.94 is 145.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current Receivables Turnover of 12.94 is 145.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current Receivables Turnover is 12.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.28 — trading 16.3% above its estimated fair value. The current Receivables Turnover is 12.94 and 145.3% above the Biotechnology industry median of 5.28. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For IGC Pharma (IGC), the current Receivables Turnover is 12.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.28 is trading 16.3% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
Receivables Turnover: 12.94
GF Value™: $0.24 vs. price of $0.28 (16.3% above fair value)
Industry Position: 145.3% above the Biotechnology median (#54 of 838)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
